Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.34 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.34 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31529230 | 0.80 | PAX8 (0.52) | PAX8BRAF | |
| SCHEMBL31529181 | 0.78 | PAX8 (0.53) | IRAK4PAX8BRAFTNNI3KADK | |
| SCHEMBL11652071 | 0.77 | PAX8 (0.37) | PAX8ADKCA1CA2 | |
| SCHEMBL11652097 | 0.77 | PAX8 (0.37) | PAX8ADKCA1CA2 | |
| SCHEMBL31529222 | 0.74 | IRAK4 (0.41) | IRAK4PAX8 | |
| SCHEMBL31529150 | 0.74 | IRAK4 (0.41) | IRAK4PAX8EGFR | |
| SCHEMBL31529092 | 0.74 | IRAK4 (0.41) | IRAK4PAX8 | |
| SCHEMBL31529204 | 0.72 | PAX8 (0.44) | IRAK4PAX8 | |
| SCHEMBL31529122 | 0.66 | IRAK4 (0.42) | IRAK4ERBB4 | |
| SCHEMBL17612653 | 0.64 | ADK (0.44) | ADKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |